Literature DB >> 11919424

Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression.

Peter Valent1, Cem Akin, Wolfgang R Sperr, Hans-Peter Horny, Dean D Metcalfe.   

Abstract

Systemic mastocytosis (SM) is a clonal disease that shows an either indolent or an aggressive clinical course. Utilizing established criteria, indolent SM can readily be discriminated from the rare aggressive subvariants of SM in most cases. In a small group of patients, however, clinical and laboratory parameters are indicative of slow progression without signs of aggressive disease or an associated hemopoietic neoplasm. These SM patients exhibit a high burden of mast cells, hypercellular marrow and organomegaly. Because of the 'intermediate' course and uncertain prognosis, these cases have been referred to as smouldering SM. In the present article, we discuss clinical and laboratory findings in smouldering SM and review the current literature. In addition, the pathophysiology of this novel subtype of SM is discussed. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 11919424     DOI: 10.1159/000048185

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  6 in total

Review 1.  Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Cem Akin
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 2.  Systemic mastocytosis: a gastroenterological perspective.

Authors:  Hamish Philpott; Paul Gow; Peter Crowley; Sanjay Nandurkar; Jo Douglass; Peter R Gibson
Journal:  Frontline Gastroenterol       Date:  2011-09-10

Review 3.  Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap.

Authors:  Miguel Piris-Villaespesa; Ivan Alvarez-Twose
Journal:  Front Pharmacol       Date:  2020-04-14       Impact factor: 5.810

Review 4.  Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders.

Authors:  P Valent
Journal:  Clin Exp Allergy       Date:  2014-07       Impact factor: 5.018

Review 5.  The serum tryptase test: an emerging robust biomarker in clinical hematology.

Authors:  Peter Valent; Wolfgang R Sperr; Karl Sotlar; Andreas Reiter; Cem Akin; Jason Gotlib; Hans-Peter Horny; Michel Arock
Journal:  Expert Rev Hematol       Date:  2014-08-28       Impact factor: 2.929

Review 6.  Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis.

Authors:  Francesco Mannelli
Journal:  Ann Hematol       Date:  2020-11-06       Impact factor: 3.673

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.